For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230206:nRSF0804Pa&default-theme=true
RNS Number : 0804P Faron Pharmaceuticals Oy 06 February 2023
Faron Pharmaceuticals Oy
("Faron" or "Company")
Update to Faron's Financial Calendar for 2023
Company announcement, February 6, 2023 at 1:00 PM (EST) / 6:00 PM (GMT) / 8:00
PM (EET)
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on tackling
difficult-to-treat cancers and inflammation via precision immunotherapy, today
announces an update to its financial reporting calendar for 2023.
The Company's financial statement release for the full year 2022 and Annual
Report 2022, including financial statements for the full year, will now be
published on Friday, March 3, 2023, at 02:00 AM (EST) / 07:00 AM (GMT) / 09:00
AM (EET), rather than on Thursday, March 2, 2023, as had been previously
communicated.
The publication date of Tuesday, August 29, 2023, for Faron's half-year
financial report for the period January 1 to June 30, 2023, remains unchanged,
as does the date for the Company's annual general meeting, which is planned to
be held on Friday, March 24, 2023. A separate stock exchange notice will be
issued by Faron's board of directors to convene the meeting.
Full Year Results Virtual Briefing
Following publication of Faron's financial statement release for the full year
2022 on Friday, March 3, 2023, Dr. Markku Jalkanen, Chief Executive Officer,
and Toni Hänninen, Chief Financial Officer, will host a virtual briefing and
Q&A session for analysts on the day at 7:00 AM (EST) / 12:00 PM (GMT) /
2:00 PM (EET).
The full year results press release for 2022, presentation, virtual briefing
webcast details, and Annual Report 2022 will be made available at
www.faron.com/investors (http://www.faron.com/investors) . A replay of the
analyst briefing will be made available shortly afterwards.
For more details about the analyst briefing, please contact
Faron@consilium-comms.com (mailto:Faron@consilium-comms.com) .
For more information please contact:
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com (mailto:julia.balanova@faron.com)
investor.relations@faron.com (mailto:investor.relations@faron.com)
Phone: +1 (917) 306-6096
Faron Pharmaceuticals
Toni Hänninen
CFO
toni.hanninen@faron.com
Phone: +41 79 387 2643
Media Contact
Faron Pharmaceuticals
Jennifer Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
David Daley, Lindsey Neville, Namrata Taak
faron@consilium-comms.com (mailto:faron@consilium-comms.com)
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs caused by dysfunction of our immune system. The Company currently
has a pipeline based on the receptors involved in regulation of immune
response in oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative precision
immunotherapy with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid function. Currently in
Phase I/II clinical development as a potential therapy for patients with solid
tumors and hematologic malignancies, bexmarilimab has potential as a
single-agent therapy or in combination with other standard treatments
including immune checkpoint molecules. Traumakine is an investigational
intravenous (IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory
conditions. Traumakine is currently being evaluated by the 59th Medical Wing
of the US Air Force and the US Department of Defense for the prevention of
multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury
caused by a major trauma. Faron is based in Turku, Finland. Further
information is available at www.faron.com (http://www.faron.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCUNOBROVUURAR